Table 1 Characteristics in the study and control groups at baseline
From: Risk factors for the occurrence of visual-threatening posterior capsule opacification
Control n = 17,142 | Nd:YAG capsulotomy n = 8571 | P value | |
|---|---|---|---|
Age at baseline, mean ± SD | 72.17 ± 8.74 | 72.17 ± 8.74 | 1.0000 |
< 40 | 6 (0.04%) | 3 (0.04%) | |
40–59 | 1552 (9.05%) | 776 (9.05%) | |
60–79 | 12,030 (70.18%) | 6015 (70.18%) | |
≥ 80 | 3554 (20.73%) | 1777 (20.73%) | |
Gender | 1.0000 | ||
Female | 9608 (56.05%) | 4804 (56.05%) | |
Male | 7534 (43.95%) | 3767 (43.95%) | |
Urbanization | < 0.0001 | ||
Urban | 8921 (52.04%) | 4702 (54.86%) | |
Sub-urban | 5331 (31.1%) | 2620 (30.57%) | |
Rural | 2890 (16.86%) | 1249 (14.57%) | |
Low income | 84 (0.49%) | 34 (0.40%) | 0.2965 |
Co-morbidities | |||
Corneal disease | 1674 (9.77%) | 868 (10.13%) | 0.3597 |
DED | 1783 (10.4%) | 1010 (11.78%) | 0.0008 |
Glaucoma | 1768 (10.31%) | 1078 (12.58%) | < 0.0001 |
Uveitis | 180 (1.05%) | 115 (1.34%) | 0.0384 |
AMD | 876 (5.11%) | 510 (5.95%) | 0.0049 |
Hypertension | 9585 (55.92%) | 4769 (55.64%) | 0.6764 |
DM | 5138 (29.97%) | 2449 (28.57%) | 0.0203 |
Hyperlipidemia | 4739 (27.65%) | 2516 (29.35%) | 0.0041 |
Congestive heart failure | 1462 (8.53%) | 738 (8.61%) | 0.8253 |
Myocardial infarction | 308 (1.8%) | 145 (1.69%) | 0.5463 |
Cerebrovascular disease | 2414 (14.08%) | 1215 (14.18%) | 0.8394 |
Peripheral vascular disease | 833 (4.86%) | 435 (5.08%) | 0.4511 |
Dementia | 408 (2.38%) | 161 (1.88%) | 0.0099 |
Chronic pulmonary disease | 4363 (25.45%) | 2231 (26.03%) | 0.3174 |
Rheumatic disease | 470 (2.74%) | 241 (2.81%) | 0.7469 |
Peptic ulcer disease | 4274 (24.93%) | 2375 (27.71%) | < 0.0001 |
Liver disease | 2830 (16.51%) | 1517 (17.7%) | 0.0164 |
Hemiplegia or paraplegia | 347 (2.02%) | 146 (1.7%) | 0.0770 |
Renal disease | 1470 (8.58%) | 665 (7.76%) | 0.0253 |
Malignancy including lymphoma | 1084 (6.32%) | 540 (6.3%) | 0.9422 |
Coagulation defects | 28 (0.16%) | 12 (0.14%) | 0.6545 |